Compare TSLX & XERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TSLX | XERS |
|---|---|---|
| Founded | 2010 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.5B |
| IPO Year | 2011 | 2021 |
| Metric | TSLX | XERS |
|---|---|---|
| Price | $18.69 | $8.47 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 9 | 6 |
| Target Price | ★ $21.61 | $10.83 |
| AVG Volume (30 Days) | 486.3K | ★ 1.6M |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | ★ 10.82% | N/A |
| EPS Growth | N/A | ★ 100.00 |
| EPS | ★ 0.15 | N/A |
| Revenue | N/A | ★ $49,590,000.00 |
| Revenue This Year | N/A | $34.37 |
| Revenue Next Year | $1.20 | $22.86 |
| P/E Ratio | $125.33 | ★ N/A |
| Revenue Growth | N/A | ★ 142.67 |
| 52 Week Low | $16.04 | $5.25 |
| 52 Week High | $24.79 | $10.08 |
| Indicator | TSLX | XERS |
|---|---|---|
| Relative Strength Index (RSI) | 64.23 | 55.86 |
| Support Level | $18.50 | $8.00 |
| Resistance Level | $19.75 | $8.42 |
| Average True Range (ATR) | 0.45 | 0.31 |
| MACD | 0.15 | -0.04 |
| Stochastic Oscillator | 83.63 | 90.60 |
Sixth Street Specialty Lending Inc is a specialty finance company focused on providing flexible, fully committed financing solutions to middle market companies located in the United States of America. The company partners with other companies across a variety of industries and provides creative solutions with complex business models that may have limited access to capital. The company seeks to generate current income in U.S.-domiciled middle-market companies through direct originations of senior secured loans and, to a lesser extent, originations of mezzanine and unsecured loans and investments in corporate bonds and equity securities.
Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.